Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results

Annalisa Trama; Paolo Lasalvia; Dan Stark; Martin G. McCabe; Winette van der Graaf; Nathalie Gaspar; Lucy Metayer; Sandra J. Strauss; Rosalia Ragusa; Marcela Guevara; Damien Bennett; Luigino Dal Maso; Ana María Vizcaíno Batllés; Christina Schindera; Seyed Mohsen Mousavi; Francesco Cerza; Laura Botta; Andrea Ferrari; Salvatore Provenzano

doi:10.1016/j.ejca.2024.115212

Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results

Annalisa Trama, Paolo Lasalvia^*, Dan Stark, Martin G. McCabe, Winette van der Graaf, Nathalie Gaspar, Lucy Metayer, Sandra J. Strauss, Rosalia Ragusa, Marcela Guevara, Damien Bennett, Luigino Dal Maso, Ana María Vizcaíno Batllés, Christina Schindera, Seyed Mohsen Mousavi, Francesco Cerza, Laura Botta, Andrea Ferrari, Salvatore Provenzano

^*Corresponding author for this work

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

1 Downloads (Pure)

Abstract

Background: Epidemiological data for sarcoma in adolescents and young adults (AYAs) and across age groups are limited. We aim to: 1) update sarcoma incidence, survival, and changes over time in European AYAs; 2) provide an updated comparison of sarcoma survival in AYAs versus children and mature adults.

Methods: We calculated crude incidence rates (IR) per 100,000 European population per year from 2006 to 2013. Using the period approach, we calculated 5-year relative survival (RS) for the follow-up period 2010–2014. We estimated changes in incidence and survival for bone sarcoma (BS) and soft tissue sarcoma (STS) subtypes in AYAs in the years 2000–2013.

Findings: In European AYAs, the IR was 0.81/100,000 for BS and 1.45/100,000 for STS. Five-year RS was 69 % and 65 % for BS and STS, respectively. Compared to children, AYAs had poorer survival for Ewing sarcoma of bone, synovial sarcoma, Ewing sarcoma of soft tissue and rhabdomyosarcoma. Compared to mature adults, AYAs had higher 5-year RS for all BS and for most of the STS subtypes. In AYAs, incidence increased for a few bone and soft tissue subtypes. Survival increased mainly for BS.

Interpretation: The reason for the better survival observed in AYAs compared to mature adults is probably multifactorial. The limited improvement of STS survival in AYAs may reflect the relative absence of new drugs for STS during the study period. The increase in RS for BS might relate to general improvements in radiological and surgical approaches and radiotherapy techniques.

Original language	English
Article number	115212
Journal	European Journal of Cancer
Volume	217
Early online date	13 Jan 2025
DOIs	https://doi.org/10.1016/j.ejca.2024.115212
Publication status	Published - 25 Feb 2025

Keywords

Adolescents and young adults
Bone and soft tissue sarcoma
Incidence
Population-based cancer registries
Survival

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2024.115212Licence: CC BY-NC-ND

Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results
Copyright 2025 the authors. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Final published version, 1.26 MBLicence: CC BY-NC-ND

Cite this

Trama, A., Lasalvia, P., Stark, D., McCabe, M. G., van der Graaf, W., Gaspar, N., Metayer, L., Strauss, S. J., Ragusa, R., Guevara, M., Bennett, D., Dal Maso, L., Batllés, A. M. V., Schindera, C., Mousavi, S. M., Cerza, F., Botta, L., Ferrari, A., & Provenzano, S. (2025). Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results. European Journal of Cancer, 217, Article 115212. https://doi.org/10.1016/j.ejca.2024.115212

@article{e28a4f62e7e240cd9ddfdfaf1c84ea95,

title = "Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results",

abstract = "Background: Epidemiological data for sarcoma in adolescents and young adults (AYAs) and across age groups are limited. We aim to: 1) update sarcoma incidence, survival, and changes over time in European AYAs; 2) provide an updated comparison of sarcoma survival in AYAs versus children and mature adults. Methods: We calculated crude incidence rates (IR) per 100,000 European population per year from 2006 to 2013. Using the period approach, we calculated 5-year relative survival (RS) for the follow-up period 2010–2014. We estimated changes in incidence and survival for bone sarcoma (BS) and soft tissue sarcoma (STS) subtypes in AYAs in the years 2000–2013.Findings: In European AYAs, the IR was 0.81/100,000 for BS and 1.45/100,000 for STS. Five-year RS was 69 % and 65 % for BS and STS, respectively. Compared to children, AYAs had poorer survival for Ewing sarcoma of bone, synovial sarcoma, Ewing sarcoma of soft tissue and rhabdomyosarcoma. Compared to mature adults, AYAs had higher 5-year RS for all BS and for most of the STS subtypes. In AYAs, incidence increased for a few bone and soft tissue subtypes. Survival increased mainly for BS. Interpretation: The reason for the better survival observed in AYAs compared to mature adults is probably multifactorial. The limited improvement of STS survival in AYAs may reflect the relative absence of new drugs for STS during the study period. The increase in RS for BS might relate to general improvements in radiological and surgical approaches and radiotherapy techniques.",

keywords = "Adolescents and young adults, Bone and soft tissue sarcoma, Incidence, Population-based cancer registries, Survival",

author = "Annalisa Trama and Paolo Lasalvia and Dan Stark and McCabe, {Martin G.} and {van der Graaf}, Winette and Nathalie Gaspar and Lucy Metayer and Strauss, {Sandra J.} and Rosalia Ragusa and Marcela Guevara and Damien Bennett and {Dal Maso}, Luigino and Batll{\'e}s, {Ana Mar{\'i}a Vizca{\'i}no} and Christina Schindera and Mousavi, {Seyed Mohsen} and Francesco Cerza and Laura Botta and Andrea Ferrari and Salvatore Provenzano",

year = "2025",

month = feb,

day = "25",

doi = "10.1016/j.ejca.2024.115212",

language = "English",

volume = "217",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

Trama, A, Lasalvia, P, Stark, D, McCabe, MG, van der Graaf, W, Gaspar, N, Metayer, L, Strauss, SJ, Ragusa, R, Guevara, M, Bennett, D, Dal Maso, L, Batllés, AMV, Schindera, C, Mousavi, SM, Cerza, F, Botta, L, Ferrari, A & Provenzano, S 2025, 'Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results', European Journal of Cancer, vol. 217, 115212. https://doi.org/10.1016/j.ejca.2024.115212

TY - JOUR

T1 - Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results

AU - Trama, Annalisa

AU - Lasalvia, Paolo

AU - Stark, Dan

AU - McCabe, Martin G.

AU - van der Graaf, Winette

AU - Gaspar, Nathalie

AU - Metayer, Lucy

AU - Strauss, Sandra J.

AU - Ragusa, Rosalia

AU - Guevara, Marcela

AU - Bennett, Damien

AU - Dal Maso, Luigino

AU - Batllés, Ana María Vizcaíno

AU - Schindera, Christina

AU - Mousavi, Seyed Mohsen

AU - Cerza, Francesco

AU - Botta, Laura

AU - Ferrari, Andrea

AU - Provenzano, Salvatore

PY - 2025/2/25

Y1 - 2025/2/25

N2 - Background: Epidemiological data for sarcoma in adolescents and young adults (AYAs) and across age groups are limited. We aim to: 1) update sarcoma incidence, survival, and changes over time in European AYAs; 2) provide an updated comparison of sarcoma survival in AYAs versus children and mature adults. Methods: We calculated crude incidence rates (IR) per 100,000 European population per year from 2006 to 2013. Using the period approach, we calculated 5-year relative survival (RS) for the follow-up period 2010–2014. We estimated changes in incidence and survival for bone sarcoma (BS) and soft tissue sarcoma (STS) subtypes in AYAs in the years 2000–2013.Findings: In European AYAs, the IR was 0.81/100,000 for BS and 1.45/100,000 for STS. Five-year RS was 69 % and 65 % for BS and STS, respectively. Compared to children, AYAs had poorer survival for Ewing sarcoma of bone, synovial sarcoma, Ewing sarcoma of soft tissue and rhabdomyosarcoma. Compared to mature adults, AYAs had higher 5-year RS for all BS and for most of the STS subtypes. In AYAs, incidence increased for a few bone and soft tissue subtypes. Survival increased mainly for BS. Interpretation: The reason for the better survival observed in AYAs compared to mature adults is probably multifactorial. The limited improvement of STS survival in AYAs may reflect the relative absence of new drugs for STS during the study period. The increase in RS for BS might relate to general improvements in radiological and surgical approaches and radiotherapy techniques.

AB - Background: Epidemiological data for sarcoma in adolescents and young adults (AYAs) and across age groups are limited. We aim to: 1) update sarcoma incidence, survival, and changes over time in European AYAs; 2) provide an updated comparison of sarcoma survival in AYAs versus children and mature adults. Methods: We calculated crude incidence rates (IR) per 100,000 European population per year from 2006 to 2013. Using the period approach, we calculated 5-year relative survival (RS) for the follow-up period 2010–2014. We estimated changes in incidence and survival for bone sarcoma (BS) and soft tissue sarcoma (STS) subtypes in AYAs in the years 2000–2013.Findings: In European AYAs, the IR was 0.81/100,000 for BS and 1.45/100,000 for STS. Five-year RS was 69 % and 65 % for BS and STS, respectively. Compared to children, AYAs had poorer survival for Ewing sarcoma of bone, synovial sarcoma, Ewing sarcoma of soft tissue and rhabdomyosarcoma. Compared to mature adults, AYAs had higher 5-year RS for all BS and for most of the STS subtypes. In AYAs, incidence increased for a few bone and soft tissue subtypes. Survival increased mainly for BS. Interpretation: The reason for the better survival observed in AYAs compared to mature adults is probably multifactorial. The limited improvement of STS survival in AYAs may reflect the relative absence of new drugs for STS during the study period. The increase in RS for BS might relate to general improvements in radiological and surgical approaches and radiotherapy techniques.

KW - Adolescents and young adults

KW - Bone and soft tissue sarcoma

KW - Incidence

KW - Population-based cancer registries

KW - Survival

U2 - 10.1016/j.ejca.2024.115212

DO - 10.1016/j.ejca.2024.115212

M3 - Article

C2 - 39848113

AN - SCOPUS:85215439928

SN - 0959-8049

VL - 217

JO - European Journal of Cancer

JF - European Journal of Cancer

M1 - 115212

ER -

Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this